Effect of Intravenous Lidocaine Associated With Amitriptyline on Pain Relief and Plasma Serotonin, Norepinephrine, and Dopamine Concentrations in Fibromyalgia

Vlainich, Roberto; Issy, Adriana Machado; Sakata, Rioko Kimiko

doi:10.1097/ajp.0b013e3181ffbfde

Cited by 29 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the serotonin and norepinephrine reuptake inhibitor amitriptyline is one of the few pharmacological agents that have shown promise for reducing spinal cord injury pain and post-stroke neuropathic pain. Of relevance to our findings is that amitriptyline upregulates D1 receptor expression (Lammers et al, 2000; Huzarska et al, 2006), dopamine receptor signaling pathways (Bohm et al, 2006; Lauterbach 2012), spares dopaminergic neurons (Paumier et al, 2015), and increases dopamine levels (Dimatteo et al, 2000; Vlainich et al, 2011). …”

Section: Dopamine Receptor Function/signal Transduction In the Pagsupporting

confidence: 50%

Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion

Voulalas

Jiang

et al. 2017

Neuroscience

View full text Add to dashboard Cite

Neuropathic pain resulting from spinal cord injury is often accompanied by maladaptive plasticity of the central nervous system, including the opioid receptor-rich periaqueductal gray (PAG). Evidence suggests that sensory signaling via the PAG is robustly modulated by dopamine D1- and D2-like receptors, but the effect of damage to the spinal cord on D1 and D2 receptor protein expression and function in the PAG has not been examined. Here we show that 21 days after a T10 or C6 spinothalamic tract lesion, both mice and rats display a remarkable decline in the expression of D1 receptors in the PAG, revealed by western blot analysis. These changes were associated with a significant reduction in hindpaw withdrawal thresholds in lesioned animals compared to sham-operated controls. We investigated the consequences of diminished D1 receptor levels by quantifying D1-like receptor-mediated phosphorylation of ERK1,2 and CREB, events that have been observed in numerous brain structures. In naïve animals, western blot analysis revealed that ERK1,2, but not CREB phosphorylation was significantly increased in the PAG by the D1-like agonist SKF 81297. Using immunohistochemistry, we found that SKF 81297 increased ERK1,2 phosphorylation in the PAG of sham animals. However, in lesioned animals, basal pERK1,2 levels were elevated and did not significantly increase after exposure to SKF 81297. Our findings provide support for the hypothesis that molecular adaptions resulting in a decrease in D1 receptor expression and signaling in the PAG are a consequence of SCL.

show abstract

Section: Dopamine Receptor Function/signal Transduction In the Pagsupporting

confidence: 50%

Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion

Voulalas

Jiang

et al. 2017

Neuroscience

View full text Add to dashboard Cite

show abstract

“…Four thousand three hundred twenty-one records were found after the initial search (Figure 1). Full texts of 42 studies were reviewed, of which 16 studies were excluded: 2 were duplicate publications (23, 24), 4 were non-randomized (25–28), 2 were non-blinded (29, 30), 2 were retrospective studies (31, 32), 2 had used lignocaine for prevention of post-herpetic neuralgia (phn) (33, 34), 3 did not use a placebo (35–37), while the remaining study did not use any controls (38). A total of 26 articles were included in the systematic review (11–14, 16–19, 39–56).…”

Section: Resultsmentioning

confidence: 99%

Intra-Venous Lidocaine to Relieve Neuropathic Pain: A Systematic Review and Meta-Analysis

Zhu

Zhou

et al. 2019

Front. Neurol.

View full text Add to dashboard Cite

Background: The prevalence of neuropathic pain is estimated to be between 7 and 10% in the general population. The efficacy of intravenous (IV) lidocaine has been studied by numerous clinical trials on patients with neuropathic pain. The aim of this systematic review and meta-analysis was to evaluate the efficacy of IV lidocaine compared with a placebo for neuropathic pain and secondly to assess the safety of its administration.Methods: A literature search on PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials), and Google scholar databases was performed for relevant studies published up to February 2019. Randomized controlled trials (RCTs) evaluating IV lidocaine treatment for pain relief in patients with neuropathic pain were included.Results: 26 articles met the inclusion criteria. Patients with varied etiology of neuropathic pain were among the patient samples of these studies. Fifteen articles were included for quantitative analysis. Lidocaine was superior to a placebo in relieving neuropathic pain in the early post-infusion period [Mean Difference (MD) = −11.9; 95% Confidence interval (CI): −16.8 to −7; p < 0.00001]. Multiple infusions of lidocaine over a period of 4 weeks, however, had no significant effect on reliving neuropathic pain (MD = −0.96; 95% CI: −2.02 to 0.11; p = 0.08). IV lidocaine was also associated with a significant number of adverse events compared to a placebo [Odds Ratio (OR) = 7.75; 95% CI: 3.18–18.92; p < 0.00001].Conclusion: Our study indicates that while IV lidocaine is effective in pain control among patients with neuropathic pain in the immediate post-infusion period, it does not have a long-lasting, persistent effect. IV infusions of the drug are associated with an increased risk of side effects compared to a placebo. However, the risk of serious adverse events is negligible. Further, well-designed RCTs evaluating the effects of various dosages and infusion periods of IV lidocaine are required to provide clear guidelines on its clinical use.

show abstract

“…Although action at muscarinic and histamine receptors of antidepressants has been related to the adverse cardiotoxicity and gastrointestinal disturbance, and sedative properties respectively, antinociceptive effects may also be achieved by actions at these receptors [27,28]. The efficacy of antidepressant drugs tested as treatments of fibromyalgia on the characteristic symptoms and quality of life assessments are summarized in Table 2 [29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70]. …”

Section: Pharmacology Of Antidepressants and Fibromyalgiamentioning

confidence: 99%

A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia

Lawson

2017

Biomedicines

View full text Add to dashboard Cite

Fibromyalgia is a complex chronic condition characterized by pain, physical fatigue, sleep disorder and cognitive impairment. Evidence-based guidelines recommend antidepressants as treatments of fibromyalgia where tricyclics are often considered to have the greatest efficacy, with amitriptyline often being a first-line treatment. Amitriptyline evokes a preferential reduction in pain and fatigue of fibromyalgia, and in the Fibromyalgia Impact Questionnaire (FIQ) score, which is a quality of life assessment. The multimodal profile of the mechanisms of action of amitriptyline include monoamine reuptake inhibition, receptor modulation and ion channel modulation. Several of the actions of amitriptyline on multiple nociceptive and sensory processes at central and peripheral locations have the potential to act cumulatively to suppress the characteristic symptoms of fibromyalgia. Greater understanding of the role of these mechanisms of action of amitriptyline could provide further clues to the pathophysiology of fibromyalgia and to a preferable pharmacological profile for future drug development.

show abstract

Effect of Intravenous Lidocaine Associated With Amitriptyline on Pain Relief and Plasma Serotonin, Norepinephrine, and Dopamine Concentrations in Fibromyalgia

Abstract: Combined administration of 240 mg intravenous lidocaine (once a week) and 25 mg amitriptyline for 4 weeks did not modify pain intensity or plasma serotonin, norepinephrine, or dopamine concentrations in fibromyalgia patients.

Cited by 29 publications

References 41 publications

Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion

Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion

Intra-Venous Lidocaine to Relieve Neuropathic Pain: A Systematic Review and Meta-Analysis

A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia

Contact Info

Product

Resources

About